Recent multi-omic clocks demonstrate that integrating DNA methylation, proteomics, metabolomics, and transcriptomics improves prediction of health outcomes and mortality [1][2]. Longitudinal biomarker velocity models further show that rates of change outperform static measures for future age estimation [2]. Simultaneously, single-nucleus ATAC-seq reveals cell-type-specific heterochromatin loss, exemplified by reduced Igf1 promoter accessibility in excitatory neurons during aging [4]. Weighted nearest neighbor alignment of scRNA-seq and scATAC-seq captures chromatin states that precede transcriptional shifts [3]. These advances highlight a gap: most clocks treat omics layers as static correlates rather than dynamic mediators of systemic aging.

We hypothesize that progressive chromatin accessibility changes in circulating immune mononuclear cells act as an early upstream driver of multi-organ aging phenotypes. Specifically, age‑related erosion of repressive marks at promoters of pro‑inflammatory genes (e.g., NFKB1, IL6) in monocytes and neutrophils increases their transcriptional burst frequency. This heightened activity loads specific miRNA and protein cargo into extracellular vesicles (EVs) that are released into the plasma. EV cargo then travels to distant tissues, where it alters local chromatin states—either by delivering transcriptional regulators that modify nucleosome positioning or by activating signaling cascades that recruit histone modifiers. Consequently, tissue‑specific methylation clocks (e.g., epigenetic age of liver, muscle, or brain) exhibit accelerated drift not because of intrinsic cell‑autonomous damage but due to immune‑derived epigenetic reprogramming.

This hypothesis generates three testable, falsifiable predictions. First, longitudinal scATAC‑seq of PBMCs collected at 6‑month intervals will show increasing accessibility at inflammatory gene loci that predicts subsequent changes in plasma EV miRNA profiles (measured by small‑RNA seq) with a lead time of at least 3 months. Second, experimental depletion of circulating monocytes in aged mice (using clodronate liposomes) will attenuate the age‑associated accumulation of EV‑derived miR‑155 in target tissues and slow the advancement of organ‑specific methylation clocks relative to untreated controls. Third, pharmacological inhibition of EV release (e.g., with GW4869) in middle‑aged animals will decouple PBMC chromatin accessibility shifts from downstream tissue methylation changes, preserving organ‑specific epigenetic age despite ongoing immune chromatin opening.

Standardized multi‑omic cohorts such as UK Biobank’s imaging‑multi‑omics project provide the necessary longitudinal methylation, proteomics, and metabolite data [6]. Adding serial PBMC collection for scATAC‑seq and EV profiling would enable direct testing of the first prediction. Mouse studies can address the second and third predictions using existing clonally traced immune ablation and EV inhibition approaches. If validated, this model would reposition immune chromatin dynamics as a causal lever that propagates aging across organs, offering a mechanistic bridge between predictive multi‑omic clocks and actionable interventions.